NCT03785249 2025-09-30Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1Mirati Therapeutics Inc.Phase 1/2 Active not recruiting731 enrolled 2 FDA
NCT04418661 2025-05-29Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced MalignanciesSanofiPhase 1/2 Terminated65 enrolled 32 charts